ORM-13070 | CAS# 1227170-43-5 | antagonist radioligand for the α2C adrenoceptor subtype

MedKoo Cat#: 414635 | Name: ORM-13070

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ORM-13070 is a selective antagonist radioligand for the α2C adrenoceptor subtype. ORM-13070 C-11 is under investigation in clinical trial.

Chemical Structure

ORM-13070

CAS#1227170-43-5

Theoretical Analysis

MedKoo Cat#: 414635

Name: ORM-13070

CAS#: 1227170-43-5

Chemical Formula: C20H25N3O3

Exact Mass: 355.1896

Molecular Weight: 355.44

Elemental Analysis: C, 67.58; H, 7.09; N, 11.82; O, 13.50

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

ORM-13070; ORM13070; ORM 13070

IUPAC/Chemical Name

(S)-1-((2,3-Dihydrobenzo(b)(1,4)dioxin-2-yl)methyl)-4-(3-(methoxymethyl)pyridin-2-yl)piperazine

InChi Key

VGIYMYGMVXPMKV-KRWDZBQOSA-N

InChi Code

InChI=1S/C20H25N3O3/c1-24-14-16-5-4-8-21-20(16)23-11-9-22(10-12-23)13-17-15-25-18-6-2-3-7-19(18)26-17/h2-8,17H,9-15H2,1H3/t17-/m0/s1

SMILES Code

COCC1=CC=CN=C1N2CCN(C[C@H]3COC4=CC=CC=C4O3)CC2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 355.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Shahid M, Rinne JO, Scheinin M, Virta J, Marjamäki P, Solin O, Arponen E, Sallinen J, Kuokkanen K, Rouru J. Application of the PET ligand [11C]ORM-13070 to examine receptor occupancy by the α2C-adrenoceptor antagonist ORM-12741: translational validation of target engagement in rat and human brain. EJNMMI Res. 2020 Dec 9;10(1):152. doi: 10.1186/s13550-020-00741-y. PMID: 33296042; PMCID: PMC7726058. 2: Luoto P, Suilamo S, Oikonen V, Arponen E, Helin S, Herttuainen J, Hietamäki J, Holopainen A, Kailajärvi M, Peltonen JM, Rouru J, Sallinen J, Scheinin M, Virta J, Virtanen K, Volanen I, Roivainen A, Rinne JO. ¹¹C-ORM-13070, a novel PET ligand for brain α₂C-adrenoceptors: radiometabolism, plasma pharmacokinetics, whole-body distribution and radiation dosimetry in healthy men. Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1947-56. doi: 10.1007/s00259-014-2782-y. Epub 2014 May 17. PMID: 24838249. 3: Lehto J, Hirvonen MM, Johansson J, Kemppainen J, Luoto P, Naukkarinen T, Oikonen V, Arponen E, Rouru J, Sallinen J, Scheinin H, Vuorilehto L, Finnema SJ, Halldin C, Rinne JO, Scheinin M. Validation of [(11) C]ORM-13070 as a PET tracer for alpha2c -adrenoceptors in the human brain. Synapse. 2015 Mar;69(3):172-81. doi: 10.1002/syn.21798. Epub 2015 Jan 8. PMID: 25530024. 4: Finnema SJ, Hughes ZA, Haaparanta-Solin M, Stepanov V, Nakao R, Varnäs K, Varrone A, Arponen E, Marjamäki P, Pohjanoksa K, Vuorilehto L, Babalola PA, Solin O, Grimwood S, Sallinen J, Farde L, Scheinin M, Halldin C. Amphetamine decreases α2C-adrenoceptor binding of [11C]ORM-13070: a PET study in the primate brain. Int J Neuropsychopharmacol. 2014 Dec 13;18(3):pyu081. doi: 10.1093/ijnp/pyu081. PMID: 25522417; PMCID: PMC4360244. 5: Lehto J, Johansson J, Vuorilehto L, Luoto P, Arponen E, Scheinin H, Rouru J, Scheinin M. Sensitivity of [(11)C]ORM-13070 to increased extracellular noradrenaline in the CNS - a PET study in human subjects. Psychopharmacology (Berl). 2015 Nov;232(21-22):4169-78. doi: 10.1007/s00213-015-3941-y. Epub 2015 Apr 29. PMID: 25918111. 6: Lehto J, Virta JR, Oikonen V, Roivainen A, Luoto P, Arponen E, Helin S, Hietamäki J, Holopainen A, Kailajärvi M, Peltonen JM, Rouru J, Sallinen J, Virtanen K, Volanen I, Scheinin M, Rinne JO. Test-retest reliability of (11)C-ORM-13070 in PET imaging of α2C-adrenoceptors in vivo in the human brain. Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):120-7. doi: 10.1007/s00259-014-2899-z. Epub 2014 Sep 9. PMID: 25201008. 7: Arponen E, Helin S, Marjamäki P, Grönroos T, Holm P, Löyttyniemi E, Någren K, Scheinin M, Haaparanta-Solin M, Sallinen J, Solin O. A PET Tracer for Brain α2C Adrenoceptors, (11)C-ORM-13070: Radiosynthesis and Preclinical Evaluation in Rats and Knockout Mice. J Nucl Med. 2014 Jul;55(7):1171-7. doi: 10.2967/jnumed.113.135574. Epub 2014 May 5. PMID: 24799619. 8: Lehto J, Scheinin A, Johansson J, Marjamäki P, Arponen E, Scheinin H, Scheinin M. Detecting a dexmedetomidine-evoked reduction of noradrenaline release in the human brain with the alpha2C-adrenoceptor PET ligand [11C]ORM-13070. Synapse. 2016 Feb;70(2):57-65. doi: 10.1002/syn.21872. Epub 2015 Nov 26. PMID: 26562363. 9: Savolainen K, Ihalainen J, Hämäläinen E, Tanila H, Forsberg MM. Phencyclidine-induced cognitive impairments in repeated touchscreen visual reversal learning tests in rats. Behav Brain Res. 2021 Apr 23;404:113057. doi: 10.1016/j.bbr.2020.113057. Epub 2020 Dec 11. PMID: 33316322. 10: Uys MM, Shahid M, Harvey BH. Therapeutic Potential of Selectively Targeting the α2C-Adrenoceptor in Cognition, Depression, and Schizophrenia-New Developments and Future Perspective. Front Psychiatry. 2017 Aug 14;8:144. doi: 10.3389/fpsyt.2017.00144. PMID: 28855875; PMCID: PMC5558054.